Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy

Table 2 Univariate analysis of PFS ( log-rank test)

Clinical parameter	n (% )	Median (months)	P value
Age			0.3447
○ < 65	60 (81.1%)	17.4
○ > 65	14 (18.9%)	20.0
FIGO stage at diagnosis
○ Early (I,II)	15 (20.3%)	76.3%†	0.0040*
○ Advanced (III,IV)	59 (79.7%)	33.3%†	0.0040*
Histopathologic cell type
○ serous	37 (50%)	16.8	0.0202*
○ others	37 (50%)	31.5	0.0202*
Residual tumor size			0.0005*
○ <1 cm	48 (64.9%)	28.3
○ > 1 cm	26 (35.1%)	8.9
Performance status (ECOG)			0.1388
○ 0-1	69 (93.2%)	20.0
○ 2	5 (6.7%)	17.4
Tumor grade			0.4788
○ G1,G2	31 (41.9%)	26.7
○ G3, unknown	43 (58.1%)	16.6
Tau expression			0.0355*
○ negative	19 (25.6%)	28.7
○ positive	55 (74.3%)	15.9

†− if median was not achieved, the results were described as a percentage of patients with 2 years PFS *- statistical significance.

ISSN: 1756-9966